Worldwide Clinical Trials
DECEMBER 7, 2023
Amidst a shifting clinical landscape characterized by increasingly complex trial designs and growing patient subpopulations, many contract research organizations (CROs) have adopted a “one-stop-shop” strategic approach. As a result, various CROs have undergone significant consolidations and acquisitions of specialized capabilities to address the escalating complexity in clinical trials.
Bio Pharma Dive
DECEMBER 7, 2023
The funding is indicative of investor interest in an area of drug research that involves at least a dozen startups and multiple publicly traded companies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 7, 2023
The FDA has granted fast track designation to Solid Biosciences’s gene therapy SGT-003 for the treatment of DMD.
Pharma Times
DECEMBER 7, 2023
The disease is one of the leading causes of cancer deaths in the UK - News - PharmaTimes
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
DECEMBER 7, 2023
Japan has granted approval for the sBLA of Bristol-Myers Squibb (BMS) for Abecma to treat relapsed or refractory multiple myeloma (RRMM).
Fierce Pharma
DECEMBER 7, 2023
When it comes to manufacturing cell therapies, it's often said that the "process is the product." But churning out these complex, individualized drugs has routinely tripped up even the industry's l | In recent months, Novartis has faced scrutiny from the FDA over Kymriah production shortfalls, a newly posted letter shows. The company says it's working to address the situation.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
DECEMBER 7, 2023
Partnerships for prevention: Biopharma, patients, and digital technology Mike.
Pharmaceutical Technology
DECEMBER 7, 2023
GlobalData’s report assesses the drugs in the Calcitonin Gene Related Peptide Type 1 Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Antidote
DECEMBER 7, 2023
Chronic spontaneous urticaria, also called chronic idiopathic urticaria, is a type of chronic hives that come and go unexpectedly. These hives persist daily for a minimum of six weeks without a clear cause or trigger. While this condition can affect anyone at any point, women experience it twice as often as men , and it’s most common between the ages of 20 and 40.
Pharmaceutical Technology
DECEMBER 7, 2023
GlobalData’s report assesses the drugs in the Calcitonin Gene Related Peptide Type 1 Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
pharmaphorum
DECEMBER 7, 2023
Treatment with Eli Lilly’s JAK inhibitor Olumiant has been shown to preserve the function of insulin-producing pancreatic beta cells in patients with type 1 diabetes, potentially opening up a whole new avenue of therapy.
Pharmaceutical Technology
DECEMBER 7, 2023
The companies presented positive Phase Ib data at the 2023 SABCS meeting, and announced plans to expand the protein degrader programme.
pharmaphorum
DECEMBER 7, 2023
AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics which spun out of Pfizer in 2018.
Pharmaceutical Technology
DECEMBER 7, 2023
The Bill & Melinda Gates Foundation grant will fund the development of dissolvable microneedle array patches for administering mRNA therapies.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
DECEMBER 7, 2023
In this latest instalment of the pharmaphorum podcast, web editor Nicole Raleigh speaks with David Solomon, CEO of Mithra Pharmaceuticals, about the current women’s health landscape and what Mithra is doing on an international scale to ameliorate that.
Pharmaceutical Technology
DECEMBER 7, 2023
Sterile filling is a critical step in pharmaceutical primary packaging. However, during this process, some drug product loss is inevitable.
pharmaphorum
DECEMBER 7, 2023
Biofidelity’s ASPYRE: The future is bright for oncology Mike.
Pharmaceutical Technology
DECEMBER 7, 2023
Synplogen and Ginkgo Bioworks have signed an MOU to expedite DNA manufacturing and gene therapy platform services in Japan.
BioSpace
DECEMBER 7, 2023
As Vertex and CRISPR Therapeutics’ exa-cel and Verve Therapeutics’ VERVE-101 move forward, questions remain about possible drawbacks of such therapies.
Pharmaceutical Technology
DECEMBER 7, 2023
If approved in June 2024, Ipsen and Genfit’s elafibranor will compete with Intercept’s Ocaliva as second-line treatment options for PBC.
pharmaphorum
DECEMBER 7, 2023
Medtech giant Medtronic has decided not to go ahead with a planned acquisition of EOFlow, a developer of patch-based insulin pumps, saying that there have been “multiple breaches” of their takeover agreement.
Pharmaceutical Technology
DECEMBER 7, 2023
AbbVie has signed a definitive agreement for the acquisition of Cerevel Therapeutics for a deal value of nearly $8.7bn in cash.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Intouch Solutions
DECEMBER 7, 2023
We are fortunate that our leadership at EVERSANA INTOUCH strives to grow and develop forward-thinking and innovative teams, all while keeping an eye on business growth and providing top-notch services to our clients. Nathan Stewart, SVP, SEO & Content Strategy, is one of those leaders, and was recently highlighted in “20 to Know in Advertising in KC,” published by the Kansas City Business Journal.
Pharmaceutical Technology
DECEMBER 7, 2023
Dr Reddy's Laboratories has signed a licence agreement with Coya Therapeutics to develop and commercialise COYA 302 to treat ALS.
Fierce Pharma
DECEMBER 7, 2023
In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little. | In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little with Johnson & Johnson.
pharmaphorum
DECEMBER 7, 2023
Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on earlier predictions.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Fierce Pharma
DECEMBER 7, 2023
Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer (NSCLC). | Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer just as its TIGIT program goes up in flames.
Pharma Times
DECEMBER 7, 2023
Around 20,000 children are admitted to ICUs every year in the UK - News - PharmaTimes
Fierce Pharma
DECEMBER 7, 2023
It’s been more than three years since Bristol Myers Squibb’s powerhouse immuno-oncology combination treatment of Opdivo and Yervoy has scored a combined FDA approval. | It’s been more than three years since Bristol Myers Squibb’s powerhouse immuno-oncology combination treatment of Opdivo and Yervoy has scored a combined FDA approval. But the duo could be on its way to a new endorsement based on a phase 3 trial that shows it can keep certain first-line colorectal cancer patients alive longer than
Pharmaceutical Technology
DECEMBER 7, 2023
GlobalData’s report assesses the drugs in the Alpha 2C Adrenergic Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
341 
Let's personalize your content